Drug major Cipla's consolidated net profit remained flat at Rs 259.66 crore for the quarter ended March 31.
The company had posted a net profit of Rs 260.69 crore in the corresponding period previous fiscal, Cipla said in a filing to the BSE.
Consolidated total income from operations, however, rose to Rs 3,092.69 crore in the quarter under consideration from Rs 2,533.38 crore year-ago.
For the full financial year, the net profit stood at Rs 1,180.77 crore as against Rs 1,388.41 crore in the previous year.
Total income of the company rose to Rs 11,345.44 crore during financial year 2015, as against Rs 10,173.39 crore year-ago.
For the March quarter, domestic sales grew by 20.7 per cent to Rs 1,086 crore, up from Rs 900 crore during Q4 last year.
Globally, while the formulations exports rose 29.7 per cent to Rs 1,690 crore for the quarter, up from Rs 1,303 crore in January-March period, the exports of APIs declined to Rs 205 crore from Rs 240 crore.
In a separate filing, Cipla said the board has recommended payment of dividend of Rs 2 per equity share for 2014-15.
Shares of Cipla closed at Rs 650.45 per scrip on the BSE, up 1.10 per cent from its previous close.
